{"id":692346,"date":"2022-10-05T08:16:15","date_gmt":"2022-10-05T12:16:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"modified":"2022-10-05T08:16:15","modified_gmt":"2022-10-05T12:16:15","slug":"crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","title":{"rendered":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ZUG, Switzerland and BOSTON, Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37<sup>th<\/sup> Annual Meeting, taking place in Boston, MA or virtually from November 8 to 12, 2022.<\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0CTX130 allogeneic CRISPR-Cas9\u2013engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC study<br \/><strong>Abstract Number and Type:<\/strong> 558, oral<br \/><strong>Session Number:<\/strong> 113, Cellular Therapies + Bispecifics<br \/><strong>Date and Time:\u00a0<\/strong>Thursday, November 10, 2022, 5:37 PM ET<\/p>\n<p><strong>Title:<\/strong>\u00a0CRISPR\/Cas9 gene-edited, allogeneic anti-CD83 CAR-T cells demonstrate potent activity in GvHD and AML tumor models<br \/><strong>Abstract Number and Type:<\/strong> 367, poster <br \/><strong>Date and Time:\u00a0<\/strong>Thursday November 10, 2022, 9:00 am &#8211; 9:00 pm<\/p>\n<p align=\"justify\">\n        <strong>About CRISPR Therapeutics<br \/><\/strong>CRISPR Therapeutics\u00a0is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR\/Cas9 platform. CRISPR\/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA.\u00a0CRISPR Therapeutics\u00a0has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts,\u00a0CRISPR Therapeutics\u00a0has established strategic partnerships with leading companies including\u00a0Bayer, Vertex Pharmaceuticals\u00a0and\u00a0ViaCyte, Inc.\u00a0CRISPR Therapeutics AG\u00a0is headquartered in\u00a0Zug, Switzerland, with its wholly-owned\u00a0U.S.\u00a0subsidiary,\u00a0CRISPR Therapeutics, Inc., and R&amp;D operations based in\u00a0Boston, Massachusetts, and business offices in\u00a0San Francisco, California\u00a0and\u00a0London, United Kingdom. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8igitMaOjD9fsI25rOr1AeTpb1enyrsl5X5L9jErDOeW2tTXhn_rXP7qCQz4N_2YH3uP9gn5JDFtEIhrJfAAmA==\" rel=\"nofollow noopener\" target=\"_blank\">www.crisprtx.com<\/a>.<\/p>\n<p align=\"justify\">CRISPR THERAPEUTICS<sup>\u00ae<\/sup> word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Susan Kim<br \/>+1-617-307-7503<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=46R1asWViI35BeWNqq2_BPF4Ns5b4LeRzS-Kca-sY7bJloORuzfS0aAJ23SgoYDlzZBGkEowScg008miu4FoticGgrpVDfSG-Gw9-lLXbig=\" rel=\"nofollow noopener\" target=\"_blank\">susan.kim@crisprtx.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Rachel Eides<br \/> +1-617-315-4493<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vrwafl255RD5UgVwjLMcusiKMwcK69NJ7GHGcJI6TlrsC86eYCzN1Kfga-UJ6aPSY2tZibm2Vy6Cqh3UmpLFYfDyxvG-1yGvwpEN-jpGTw4=\" rel=\"nofollow noopener\" target=\"_blank\">rachel.eides@crisprtx.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjEwYzE0MDAtYTU3MS00ZGNkLWEzNmItNGMzNDc0YjEzYjAwLTEwNjE0ODI=\/tiny\/CRISPR-Therapeutics-AG.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, MA or virtually from November 8 to 12, 2022. Title:\u00a0CTX130 allogeneic CRISPR-Cas9\u2013engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC studyAbstract Number and Type: 558, oralSession Number: 113, Cellular Therapies + BispecificsDate and Time:\u00a0Thursday, November 10, 2022, 5:37 PM ET Title:\u00a0CRISPR\/Cas9 gene-edited, allogeneic anti-CD83 CAR-T cells demonstrate potent activity in GvHD and AML tumor modelsAbstract Number and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692346","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, MA or virtually from November 8 to 12, 2022. Title:\u00a0CTX130 allogeneic CRISPR-Cas9\u2013engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC studyAbstract Number and Type: 558, oralSession Number: 113, Cellular Therapies + BispecificsDate and Time:\u00a0Thursday, November 10, 2022, 5:37 PM ET Title:\u00a0CRISPR\/Cas9 gene-edited, allogeneic anti-CD83 CAR-T cells demonstrate potent activity in GvHD and AML tumor modelsAbstract Number and &hellip; Continue reading &quot;CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:16:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\",\"datePublished\":\"2022-10-05T12:16:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"name\":\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=\",\"datePublished\":\"2022-10-05T12:16:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk","og_description":"ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, MA or virtually from November 8 to 12, 2022. Title:\u00a0CTX130 allogeneic CRISPR-Cas9\u2013engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC studyAbstract Number and Type: 558, oralSession Number: 113, Cellular Therapies + BispecificsDate and Time:\u00a0Thursday, November 10, 2022, 5:37 PM ET Title:\u00a0CRISPR\/Cas9 gene-edited, allogeneic anti-CD83 CAR-T cells demonstrate potent activity in GvHD and AML tumor modelsAbstract Number and &hellip; Continue reading \"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:16:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","datePublished":"2022-10-05T12:16:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"wordCount":327,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","name":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=","datePublished":"2022-10-05T12:16:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQxNSM1MTg3Mjc3IzIwNDk5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692346"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692346\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}